Shop

Publicity, regulation tightening reins on use of KOLs

Time may be right to makeover the investigator brochure

Keeping potential patients connected to trials

Sponsors, CROs demanding more from pre-study site visits

CRCs workload up: relative pay declining

As IRB industry grows up, consolidation comes knocking

E-payment services for study volunteers catching on

Complex oncology trials pose challenges for CROs, sites

Investigator-initiated trials see dramatic drop

Sponsors seeking preferred relationships with best sites

Patient-driven drug development goes prime time

Is more investigator training on the horizon?

Western Europe sees drop in active investigators

Traditional patient recruitment still missing timelines

Newer sites most optimistic about the future

Risk-based monitoring slow to catch on with industry

Global sites see growth in trials, revenue, staffing

Industry struggles with prospect of trials leaving U.S.

Living in a post-M&A world of CROs

Sites struggle with burden, blessing of multiple technologies

Anticipating the rise of virtual drug development

Closing investigative site operations a complex process

Site landscape shrinking, losing most active PIs

Social media has sponsors losing control of their message